-
Authors Showcase the Highest-Rated Scientific Abstracts during Opening Plenary
In the first of three plenary sessions, researchers from around the world presented groundbreaking research on glucagon-like peptide-1 receptor agonist use, the drug rosnilimab, artificial intelligence, anti-topoisomerase 1 antibodies, and use of a weekly triple hormone receptor agonist in rheumatic disease.
More news from #ACR26
-
Newly Defined Sources of Neoantigens and New Clinical Trial Data Highlight Year in Review
Presenters William Robinson, MD, PhD, and Liana Fraenkel, MD, MPH, shared several noteworthy developments in basic and clinical science, as well as outcomes from multiple studies.
-
ILD Treatment Continues to Evolve as More New Therapies Arrive
In a Sunday session that also featured a pulmonologist, rheumatologist Flavia V. Castelino, MD, discussed how therapies targeting interstitial lung disease affect the extrapulmonary features of autoimmune disease.
ACR Convergence Newsmakers
-
New Therapeutic Strategies Emerge for Microvascular Antiphospholipid Syndrome
Doruk Erkan, MD, MPH, and Jason S. Knight, MD, PhD, will discuss the clinical manifestations, diagnostic considerations, management strategies, and future research opportunities for patients with MAPS.
-
Panelists to Discuss Adipose-Derived Cues in Autoimmunity
Excess adiposity is a risk factor for rheumatologic diseases. Derin Karacabeyli, MD, Kim M. Huffman, MD, PhD, and Stephen Messier, PhD, will explore adipose tissue biology and adipokine-mediated mechanisms.
-
ACR Convergence 2026 Opening Session Highlights Responsible AI in Rheumatology
Brian Anderson, MD, explored the question of how to ensure the implementation of artificial intelligence tools in the medical field—at bench and at the bedside—best serves patients.
Presenter Spotlights
